Amicus Therapeutics Reports 19.4% Increase in Quarterly Net Product Sales

Amicus Therapeutics, Inc. reported significant financial performance improvements in its latest quarterly filing, with net product sales reaching $169.1 million for the three months ended September 30, 2025, compared to $141.5 million for the same period in 2024, marking a 19.4% increase. For the nine months ending September 30, 2025, total net product sales were $449.0 million, up from $378.6 million in the prior year, reflecting a 18.6% growth. The company achieved a gross profit of $149.6 million for the third quarter, up from $128.2 million year-over-year, while operating expenses increased to $115.3 million from $106.6 million, primarily due to higher selling, general, and administrative costs.

The company’s net income attributable to common stockholders for the third quarter was $17.3 million, a notable recovery from a loss of $6.7 million in the same quarter last year. For the nine-month period, however, Amicus reported a net loss of $28.8 million, an improvement from a loss of $70.8 million in the prior year. The increase in revenue was attributed to the continued growth of its flagship products, Galafold® and Pombiliti® + Opfolda®, particularly in the U.S. and European markets, alongside favorable foreign currency exchange impacts.

Strategically, Amicus has made significant moves, including an exclusive licensing agreement with Dimerix Bioscience for the commercialization of DMX-200, a Phase 3 drug candidate for Focal Segmental Glomerulosclerosis (FSGS). This agreement, finalized on April 30, 2025, involved an upfront payment of $30 million and potential future milestone payments totaling up to $615 million, which could enhance the company’s pipeline and market presence. The company continues to focus on expanding its product offerings and geographic reach, with Galafold® now approved in over 40 countries and Pombiliti® + Opfolda® gaining traction in multiple regions.

Operationally, Amicus reported an increase in inventories to $177.9 million as of September 30, 2025, up from $118.8 million at the end of 2024, indicating preparations for increased product demand. The company’s cash and cash equivalents stood at $190.6 million, with total cash, cash equivalents, and marketable securities amounting to $263.8 million, providing a solid liquidity position to support ongoing operations and research initiatives. The workforce has also expanded, contributing to higher personnel costs, which are expected to support the company’s growth trajectory.

Looking ahead, Amicus anticipates continued investment in research and development, particularly for its pipeline candidates and the commercialization of its existing products. The company expects to incur losses through the fiscal year ending December 31, 2025, but believes its current cash position is sufficient to fund operations for at least the next 12 months. The management remains optimistic about future growth driven by product adoption and potential new therapies, while also acknowledging the risks associated with clinical trials, regulatory approvals, and market competition.